To include your compound in the COVID-19 Resource Center, submit it here.

Phase II results for Repligen's secretin

RGEN said that preliminary analysis of a U.S. Phase II trial of synthetic secretin in 136 children with autism, the product missed

Read the full 226 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE